[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
[3] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[4] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[5] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[6] |
ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei.
Discuss the safety management of medical toxic drugs in medical institutions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
|
[7] |
DING Qian, LI Boyu, ZHANG Qingxia.
Risks to storage of nitroglycerin after unsealing and ways of prevention
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 326-330.
|
[8] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[9] |
LIU Hongliang, WANG Qing, HOU Yongfang.
Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098.
|
[10] |
ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui.
Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
|
[11] |
ZHANG Qingxia, JIANG Yongxian, LI Gen, YAN Suying, WANG Yuqin.
Analysis and prevention of medication errors related to stored pharmaceuticals in National Monitoring Network for Clinical Safety Medication
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1040-1044.
|
[12] |
ZHANG Qingxia, JIANG Yongxian, DONG Yuexin, XIAN Ying, YAN Suying.
Risk analysis and precautions related to storage conditions specified in package inserts of western medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 913-918.
|
[13] |
SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu.
A comparative progress and prospect for drug technological guidances system in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
|
[14] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|
[15] |
WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong.
Factors related to ADR/ADE of albumin bound paclitaxel
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
|